Case Report
Copyright ©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Oct 15, 2020; 12(10): 1209-1215
Published online Oct 15, 2020. doi: 10.4251/wjgo.v12.i10.1209
Achievement of complete response to nivolumab in a patient with advanced sarcomatoid hepatocellular carcinoma: A case report
Shu-Guang Zhu, Hai-Bo Li, Ze-Nan Yuan, Wei Liu, Qing Yang, Ying Cheng, Wen-Jing Wang, Guo-Ying Wang, Hua Li
Shu-Guang Zhu, Hai-Bo Li, Ze-Nan Yuan, Qing Yang, Guo-Ying Wang, Hua Li, Department of Hepatic Surgery and Liver Transplantation, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou 510000, Guangdong Province, China
Hai-Bo Li, Hua Li, Liver Transplant Branch of Organ Transplant Center, Organ Transplantation Institute of Sun Yat-Sen University, Guangzhou 510000, Guangdong Province, China
Ze-Nan Yuan, Wei Liu, Guo-Ying Wang, Guangdong Key Laboratory of Liver Disease Research, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou 510000, Guangdong Province, China
Ying Cheng, Wen-Jing Wang, Department of Medicine, OrigiMed Inc., Shanghai 201100, China
Author contributions: All authors contributed to the writing of the manuscript; Wang GY conceived the study; Li H provided clinical expertise; Liu W and Yang Q assisted in data collection; Cheng Y and Wang WJ analyzed the data and participated in revising and critically assessing the report; Zhu SG, LI H, Yuan ZN, and Wang GY provided expertise in molecular and targeted therapy; all the authors read and approved the final version of the manuscript.
Supported by The National 13th Five-Year Science and Technology Plan Major Projects of China, No. 2017ZX10203205-006-001.
Informed consent statement: Informed written consent was obtained from the patient for publication of this report and any accompanying images.
Conflict-of-interest statement: Ying Cheng and Wen-Jing Wang are employees of OrigiMed Co., Ltd. No other potential conflicts of interest exist.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Guo-Ying Wang, MD, PhD, Doctor, Surgeon, Department of Hepatic Surgery and Liver Transplantation, The Third Affiliated Hospital of Sun Yat-Sen University, No. 600 Tianhe Road, Tianhe District, Guangzhou 510000, Guangdong Province, China. wanggy3@126.com
Received: March 18, 2020
Peer-review started: March 18, 2020
First decision: May 28, 2020
Revised: July 6, 2020
Accepted: September 8, 2020
Article in press: September 8, 2020
Published online: October 15, 2020
Processing time: 210 Days and 11.5 Hours
Core Tip

Core Tip: Here, we report a rare case of advanced sarcomatoid hepatocellular carcinoma (SHC), which was successfully treated with the anti-programmed cell death 1 antibody. To the best of our knowledge, this is the first case report on the successful treatment of advanced SHC using immunotherapy.